(Bloomberg) -- Dendreon Corp. more than doubled in extended trading after the company detailed a clinical trial of its cancer drug, whipsawing speculators who sent the stock tumbling as much as 69 percent before the study was released.
(Bloomberg) -- Dendreon Corp. more than doubled in extended trading after the company detailed a clinical trial of its cancer drug, whipsawing speculators who sent the stock tumbling as much as 69 percent before the study was released.
